pacDNA is transforming the field of gene regulation therapeutics with our proprietary Brushield™ oligonucleotide enhancer technology. The Brushield™ platform can rapidly generate potent clinical leads with fewer side effects at a lower dosage, delivered to non-liver sites. In preclinical models for cancer and rare genetic disorders, Brushield™ conjugates increase the drug potency by up to 100x compared to the state-of-the-art while suppressing side effects and immunogenicity. With a substantial expansion in targeted organ/disease areas and a reduction in cost, pacDNA can access an exponentially larger patient population, which underscores the economic potential of our platform as a drug candidate “production engine”. The technology is protected by multiple PCT/US patent applications (foundational patent has been granted). The Company is now beginning commercial operations in LabCentral 700, Cambridge, MA. Early accalades of the company include a $2.4M fast-track STTR award, participation in the MassBioDrive accelerator program, a Golden Ticket from BioMarin, and a Spark Award from Northeastern University.
Speaker
